☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
LaNova Medicines
LaNova Medicines Reports the Commencement of P-I Study Evaluating LM-299 for Solid Tumors and Completes Series C1 Financing Round
October 18, 2024
LaNova Medicines Entered into an Exclusive License Agreement with AstraZeneca for LM-305 to Treat Multiple Myeloma
May 15, 2023
Load more...
Back to Home
Modal title
×
Modal body text goes here.
